Table 2: Candidate vaccines under development using different platforms.
|
Platform |
Candidate vaccines (no. and %) |
||
|
PS. |
Protein subunit |
54 |
32% |
|
VVnr |
Viral Vector (non-replicating) |
21 |
13% |
|
DNA |
DNA |
16 |
10% |
|
IV |
Inactivated Virus |
22 |
13% |
|
RNA |
RNA |
41 |
24% |
|
VVr |
Viral Vector (replicating) |
4 |
2% |
|
VLP |
Virus Like Particle |
6 |
4% |
|
VVr + APC |
VVr + Antigen Presenting Cell |
2 |
1% |
|
LAV |
Live Attenuated Virus |
2 |
1% |
|
VVnr + APC |
VVnr + Antigen Presenting Cell |
1 |
1% |
|
BacAg-SpV |
Bacterial antigen-spore expression vector |
1 |
1% |
|
Total |
170 |
||
Ref: WHO COVID-19 vaccine tracker and landscape (accessed on August 5, 2022)